MX2021011105A - Lanabecestat para la perdida de peso. - Google Patents

Lanabecestat para la perdida de peso.

Info

Publication number
MX2021011105A
MX2021011105A MX2021011105A MX2021011105A MX2021011105A MX 2021011105 A MX2021011105 A MX 2021011105A MX 2021011105 A MX2021011105 A MX 2021011105A MX 2021011105 A MX2021011105 A MX 2021011105A MX 2021011105 A MX2021011105 A MX 2021011105A
Authority
MX
Mexico
Prior art keywords
weight loss
lanabecestat
indene
pyridin
prop
Prior art date
Application number
MX2021011105A
Other languages
English (en)
Inventor
Craig Shering
John Sims
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021011105A publication Critical patent/MX2021011105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente solicitud se refiere a influir en la pérdida de peso que comprende administrar una cantidad terapéuticamente eficaz de (1r,1'R,4R)-4-metoxi-5''-metil-6'-[5-(prop-1-in-1-il)piridin-3-il ]-3'H-diespiro[ciclohexano-1,2'-indeno-1',2''-imidazol]-4''-amina , o una sal farmacéuticamente aceptable de la misma (por ejemplo, la sal camsilato de (1r,1'R,4R)-4-metoxi-5''-metil-6'-[5-(prop-1-i n-1-il)piridin-3-il]-3'H-diespiro[ciclohexano-1,2'-indeno-1',2''- imidazol]-4''-amina).
MX2021011105A 2019-03-14 2020-03-13 Lanabecestat para la perdida de peso. MX2021011105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818718P 2019-03-14 2019-03-14
PCT/EP2020/056994 WO2020183021A1 (en) 2019-03-14 2020-03-13 Lanabecestat for weight loss

Publications (1)

Publication Number Publication Date
MX2021011105A true MX2021011105A (es) 2021-10-22

Family

ID=69845404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011105A MX2021011105A (es) 2019-03-14 2020-03-13 Lanabecestat para la perdida de peso.

Country Status (10)

Country Link
US (1) US20220175749A1 (es)
EP (1) EP3937935A1 (es)
JP (1) JP2022525157A (es)
KR (1) KR20210139335A (es)
CN (1) CN113573709A (es)
AU (1) AU2020234033B2 (es)
BR (1) BR112021017960A2 (es)
CA (1) CA3131753A1 (es)
MX (1) MX2021011105A (es)
WO (1) WO2020183021A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
JP2002501892A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
BRPI0413381A (pt) 2003-08-07 2006-10-17 Allergan Inc composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
US20190262327A1 (en) * 2016-03-15 2019-08-29 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta

Also Published As

Publication number Publication date
CN113573709A (zh) 2021-10-29
AU2020234033B2 (en) 2023-07-13
WO2020183021A1 (en) 2020-09-17
JP2022525157A (ja) 2022-05-11
CA3131753A1 (en) 2020-09-17
KR20210139335A (ko) 2021-11-22
BR112021017960A2 (pt) 2021-11-23
AU2020234033A1 (en) 2021-11-04
US20220175749A1 (en) 2022-06-09
EP3937935A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
UA115560C2 (uk) Фунгіцидні композиції
ME02633B (me) Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro [cikloheksan-1,2'-inden-1'2'-imidazol]-4"amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti
EP4276095A3 (en) Processes for preparing ask1 inhibitors
EP1637521A4 (en) NEW TRICYCLIC HETEROCYCLIC COMPOUND
MX2021006553A (es) Metodos para tratar trastornos neurologicos y psiquiatricos.
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
WO2017210545A8 (en) Potassium channel modulators
CR20210426A (es) Compuestos, composiciones y métodos
EP1775283A4 (en) 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1)
WO2012099942A3 (en) Methods and compositions for treating metabolic syndrome
MX2016000669A (es) Compuestos plaguicidas.
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2022003633A (es) Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
WO2021079196A3 (en) Mettl3 modulators
AU2019360428B2 (en) Pyrazole derivatives as H4 antagonist compounds
SA519401827B1 (ar) [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه
MX2021011105A (es) Lanabecestat para la perdida de peso.
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
JOP20210312A1 (ar) أملاح مقبولة صيدلانياً من [2-(3- فلورو-5- ميثان سلفونيل فينوكسي) إيثيل ](بروبيل) أمين واستخداماتها
SG11201907945YA (en) Azetidine derivative
RS54591B1 (en) UNITS FOR SUPPRESSION OF PERIPHERAL DISORDER DISORDERS INDUCED BY ANTI-CARCINOGENIC MEANS
WO2011132901A3 (en) Novel benzamide derivatives
PH12021550146A1 (en) Condensed lactam derivative
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.